FLT3 and acute myeloid leukemia: Venetoclax was also tested with gilteritinib in relapsed/refractory FLT3-mutated AML in a multicenter clinical trial (NCT03625505), leading to a 75% CRc rate with most common grade ≥ 3 AEs involving febrile neutropenia and decreased white blood cell count [68].